Sanofi Heart Drug Multaq Linked To Liver Failure

Law360, New York (January 14, 2011, 3:40 PM EST) -- The U.S. Food and Drug Administration warned Friday that Multaq, Sanofi-Aventis SA's 18-month-old drug for heart problems, may be linked to liver damage in some patients, including two women whose livers failed.

Multaq, also known by the generic name dronedarone, has been connected with cases of “rare, but severe liver injury,” the FDA said in a warning to patients and doctors.

The drug was approved in the U.S. in July 2009 to treat abnormal heart rhythm and, through October 2010, about 492,000 prescriptions were dispensed, according...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.